Management Change/Compensation Form 8 K

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 30, 2024, the Board of Directors (the "Board") of Mural Oncology plc (the "Company"), upon recommendation from the Nominating and Corporate Governance Committee of the Board, appointed George Golumbeski, Ph.D., as a director in accordance with the Company's articles of association to serve on the Board with an initial term expiring at the Company's 2025 annual general meeting. Dr. Golumbeski has not been appointed to serve on any committees of the Board. The Board has determined that Dr. Golumbeski is an "independent" director under the Nasdaq Stock Market rules.

Dr. Golumbeski is entitled to receive compensation under the Company's non-employeedirector compensation program. In accordance with this program, upon his appointment to the Board, Dr. Golumbeski received, under the Company's 2023 Stock Option and Incentive Plan, an option to purchase 15,334 ordinary shares, at an exercise price equal to $3.38 per share, the closing price of the Company's ordinary shares on the date of appointment, which option will vest and become exercisable in equal quarterly installments over three years from the date of appointment, subject to Dr. Golumbeski's continued service. In the event of a change in control of the Company, the vesting schedule of the option will accelerate in full. In addition, Dr. Golumbeski will receive annual cash compensation of $40,000 as a member of the Board, annual equity grants in accordance with the non-employeedirector compensation program and reimbursement for reasonable travel and out-of-pocketexpenses incurred in connection with attending Board meetings.

There are no arrangements or understandings between Dr. Golumbeski and any other persons pursuant to which he was appointed as a director. Dr. Golumbeski does not have any family relationships with any of the Company's directors or executive officers. There are no transactions and no proposed transactions between Dr. Golumbeski and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Dr. Golumbeski will enter into indemnification agreements with the Company and Mural Oncology, Inc., the Company's wholly owned subsidiary. The Company's form of deed of indemnification agreement and form of indemnification agreement with Mural Oncology, Inc. were filed as Exhibit 10.5 and Exhibit 10.6, respectively, to the Company's Registration Statement on Form 10 filed with the U.S. Securities and Exchange Commission on October 10, 2023.